Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)
- Conditions
- Interventions
- First Posted Date
- 2015-04-06
- Last Posted Date
- 2019-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT02409355
- Locations
- 🇺🇸
University of Maryland, Baltimore, Maryland, United States
🇺🇸California Cancer Associates for Research & Excellence, Inc., Encinitas, California, United States
🇺🇸Marin Cancer Care Inc, Greenbrae, California, United States
A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors
- First Posted Date
- 2015-01-30
- Last Posted Date
- 2020-01-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 70
- Registration Number
- NCT02350673
- Locations
- 🇩🇰
Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
🇳🇱Erasmus MC, Rotterdam, Netherlands
🇺🇸SCRI-Tennessee Oncology, Nashville, Tennessee, United States
A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread
- Conditions
- Interventions
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2023-04-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 169
- Registration Number
- NCT02322814
- Locations
- 🇺🇸
Cancer Treatment Centers of America, Newnan, Georgia, United States
🇦🇺St John of God Murdoch Hospital; Oncology West, Murdoch, Western Australia, Australia
🇧🇪Clinique Edith Cavell, Bruxelles, Belgium
A Study of Emactuzumab and Atezolizumab Administered in Combination in Participants With Advanced Solid Tumors
- First Posted Date
- 2014-12-23
- Last Posted Date
- 2020-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 221
- Registration Number
- NCT02323191
- Locations
- 🇺🇸
Dana Farber - Harvard, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center Breast & Imaging Center, New York, New York, United States
🇪🇸Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona, Navarra, Spain
A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2019-12-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 140
- Registration Number
- NCT02304393
- Locations
- 🇩🇰
Rigshospitalet; Onkologisk Klinik, København Ø, Denmark
🇨🇦University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto, Ontario, Canada
🇨🇦Jewish General Hospital / McGill University, Montreal, Quebec, Canada
Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC
- Conditions
- Interventions
- First Posted Date
- 2014-12-01
- Last Posted Date
- 2021-02-03
- Lead Sponsor
- University Hospital Tuebingen
- Target Recruit Count
- 47
- Registration Number
- NCT02303951
- Locations
- 🇩🇪
University hospital Tübingen, Tübingen, Germany
🇫🇷Department of Dermatology, University Hospital of Nantes, Nantes, France
🇫🇷Hopital Saint-Louis Hopitaux Universitaires Saint-Louis Laboisiere Fernand-Widal, Paris, France
A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)
- Conditions
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2017-12-11
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 29
- Registration Number
- NCT02298153
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸University of Washington, Seattle, Washington, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC)
- First Posted Date
- 2014-11-14
- Last Posted Date
- 2024-05-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1044
- Registration Number
- NCT02291289
- Locations
- 🇦🇷
Hospital de Gastroenterologia Dr. Bonorino Udaondo ; Servicio de Oncología, Buenos Aires, Argentina
🇧🇪Institut Jules Bordet X, Brussels, Belgium
🇧🇪Hospital Erasme, Bruxelles, Belgium
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 96
- Registration Number
- NCT02220842
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸Sloan Kettering Cancer Center, New York, New York, United States
🇫🇷Hôpital Saint-Louis, Paris, France
A Study to Assess the Safety and Tolerability of Atezolizumab in Combination With Other Immune-Modulating Therapies in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-06-25
- Last Posted Date
- 2020-05-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 158
- Registration Number
- NCT02174172
- Locations
- 🇺🇸
HonorHealth Research Institute - Bisgrove, Scottsdale, Arizona, United States
🇺🇸UCLA, Los Angeles, California, United States
🇺🇸Yale University, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.